TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04817241

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT05368324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CogFun-RV
Description: CogFun-RV intervention combines training in daily living skills, organization, task planning, time organization, emotional regulation, self-esteem and mindfulness in children and the parents. It consists of 12 sessions, each lasting 75 minutes. Parents will participate in the parental guidance and psychoeducation program with one of the two therapists assigned to the child. As it is a program of a simultaneous nature, excessive impact on the daily life of families is avoided. All sessions will be carried out individually.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CogFun-RV
Description: CogFun-RV intervention combines training in daily living skills, organization, task planning, time organization, emotional regulation, self-esteem and mindfulness in children and the parents. It consists of 12 sessions, each lasting 75 minutes. Parents will participate in the parental guidance and psychoeducation program with one of the two therapists assigned to the child. As it is a program of a simultaneous nature, excessive impact on the daily life of families is avoided. All sessions will be carried out individually.
Study: NCT06313541

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT or LDRT
Description: Radiotherapy: (1) Low dose radiotherapy (LDRT) : a dose of 2 Gy/1 Fx was given to all visible lesions in the whole body within 1 week before the first course of PD-1/PD-L1 inhibitor combined with chemotherapy (different parts of the lesion could be irradiated separately, but it was required to be completed within 1 week); (2) SBRT: patients received first-line immunotherapy combined with chemotherapy, and their response was evaluated every 6 weeks. Individualized SBRT was planned based on the treatment responses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy
Description: The control group received standard PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy as first-line treatment, and the experimental group received extra treatment response adapted hybrid radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy
Description: The control group received standard PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy as first-line treatment, and the experimental group received extra treatment response adapted hybrid radiotherapy.
Study: NCT05961696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Subcutaneous (SQ or Sub-Q) injection under the skin
Study: NCT06354881

Intervention type: DEVICE
Intervention: Transcranial Doppler Ultrasonography (TCD) during sit-stand manoeuvres
Description: TCD will be used to measure the cerebral blood flow in the middle and posterior cerebral arteries. This will be done at rest and during two sit-stand manoeuvres, whereby the participant will be asked to stand (from a seated position) and stay standing for 1 minute. The participant will then be given time to recover before repeating the manoeuvre. This will occur at the first visit and the follow-up visit 4 weeks after.
Study: NCT06550999

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laceration repair with adhesive strips
Description: Repair of the patient's facial laceration with adhesive strips

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laceration repair with sutures
Description: Repair of the patient's facial laceration with sutures
Study: NCT05583435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One-on-one professional coaching
Description: One-on-one professional coaching

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One-on-one professional coaching
Description: One-on-one professional coaching

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small-group professional coaching
Description: Small-group professional coaching
Study: NCT06284369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Developing, Evaluating and Testing Video Messages for a Smoking Cessation Campaign
Description: To explore how smokers reacted to the gain-framed and loss-framed video ad

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Message Framing
Description: Gain- framed messages in health communication are constructed by framing a particular outcome as either a benefit or a cost, relative to a specific reference poin
Study: NCT04898946

Intervention type: BIOLOGICAL
Intervention: CoronaVac Vaccine
Description: CoronaVac Vaccine

Intervention type: BIOLOGICAL
Intervention: BNT162b2 Vaccine
Description: Covid-19 BNT162b2 Vaccine
Study: NCT04817241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT05021315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% povidone iodine
Description: 50 women who received preoperative vaginal cleansing with 10% povidone iodine.
Study: NCT06651671

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myofascial release
Description: THe treatment group was instructed to lay prone on the treatment table such that the skin on their upper back was visible. Participants then received direct and indirect myofascial release for 30 seconds each, performed by the same osteopathic physician.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham (No Treatment)
Description: The medical student gently placed their hands on the patients back for 60 seconds without manipulating the tissue in any way.
Study: NCT06622083

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Students in both groups will be given 40 minutes of both theoretical and practical training on the anatomy of the pelvic floor, its contraction mechanism, function and dysfunctions, evaluation and physiotherapy and rehabilitation. Theoretical training will be given through presentation and question-answer techniques containing this information, and practical training will be given through a pelvic model and gynecological examination simulator.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education and Aerobic exercise
Description: Participants in the exercise group will undergo an aerobic exercise program using the Monark 938E Nova Ergometer and software before the training session. The bike operates with its computer software integrated with the ECG system. The aerobic exercise program will consist of 3-5 minutes of warm-up, 20 minutes of exercise, and 3-5 minutes of cool-down, performed at a moderate intensity. During the exercise session, heart rate will be recorded every 5 minutes using a Polar ECG sensor connected via Bluetooth to the 938E Nova Ergometer, while perceived exertion will be measured using Borg's 6-20 rating scale
Study: NCT06701123

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: uMAT-R mobile app with coaching component
Description: uMAT-R recovery mobile app with coaching component
Study: NCT05354167

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: muscle energy technique
Description: the subject to sit comfortably and then stabilize the subject's distal humerus with one hand, then the forearm was supinated with the therapist another hand until resistance appeared. Holding the position the subject was asked to slowly pronate the forearm that is Isometric contraction against resistance for a period of 6-10 seconds with inhale and exhale, followed by slightly increasing supination until resistance was met once again. After 5 seconds of relaxation, the procedure was repeated 5 times during a single treatment session; this technique was applied in 2 sessions for a week for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oscillating manual energy therapy
Description: It is also known as V-spread .The subject was asked to sit on a chair with the affected painful arm resting on the treatment table. Tender points were palpated. Then the therapist places the index and middle fingers of one hand in a V-shape around the tender point and placed the index finger of the other hand in the medial side of the elbow, diagonally across the located tender point. Gentle pressure was applied a few times using fingertips to the tissues alternatively from the medial and lateral sides to start the oscillations. On the initiation of oscillations, the application of pressure should be stopped and allow the oscillations to continue between the two points of contact on the subject's elbow.
Study: NCT06341439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mouthwash with chlorhexidine 0,12% and CITROX
Description: Patients use the undiluted mouthwash 2 times a day for 14 days after performing normal brushing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mouthwash with chlorhexidine 0,12%
Description: Patients use the undiluted mouthwash 2 times a day for 14 days after performing normal brushing.
Study: NCT05540366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy combined with aerobic exercise
Description: 30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions, combined with a 30 minutes aerobic exercise programme on a bike.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: 30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions (same programme than the intervention group)
Study: NCT04792073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 800 mg given intravenously over 60 minutes (+20 minutes / -10 minutes) every 2 weeks (+/- 3 days)
Study: NCT06218043

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Restrict subjects' intake of iodine-containing foods
Description: Replace subjects' iodized salt with non-iodized salt.
Study: NCT04792073

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Comprehensive Ablative Radiation Therapy
Description: Comprehensive ablative radiation therapy 24 Gy in 3 fractions every 2-3 days
Study: NCT05144724

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Volume targeted ventilation
Description: Positive pressure ventilation will be provided using a set tidal volume

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure targeted ventilation
Description: Positive pressure ventilation will be provided using a set peak inflation pressure
Study: NCT06026514

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B/HPIV3/S-6P
Description: Intranasal vaccine.
Study: NCT04633434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Talk Parenting Skill for Alexa
Description: In a 4-week period, families use at home a prototype Bedtime Routine module of the Talk Parenting program, a smart speaker app designed to provide parents with in-situ experiential support for building positive family routines. The prototype Bedtime Routine module of Talk Parenting guides families in creating a healthy bedtime routine to foster healthy sleep habits, provide experiential practice in self-regulation skills, and promote a positive parent-child relationship.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Talk Parenting Skill for Alexa
Description: In a 4-week period, families use at home a prototype Bedtime Routine module of the Talk Parenting program, a smart speaker app designed to provide parents with in-situ experiential support for building positive family routines. The prototype Bedtime Routine module of Talk Parenting guides families in creating a healthy bedtime routine to foster healthy sleep habits, provide experiential practice in self-regulation skills, and promote a positive parent-child relationship.
Study: NCT05647304

Intervention type: DEVICE
Group type: OTHER
Intervention: RGn550 5 Hz-PWM
Description: RGn550 with a 5 Hz-pulsed wave mode light emission

Intervention type: DEVICE
Group type: OTHER
Intervention: RGn550 10 Hz-PWM
Description: RGn550 with a 10 Hz-pulsed wave mode light emission
Study: NCT05753085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conavi Medical Novasight Hybrid System intervention
Description: Patients for a coronary angiogram who meet the inclusion criteria and none of the exclusion criteria are enrolled. Participants are prepared for angiography and PCI procedure in the usual way. Radial or femoral artery cannulation is done under local anaesthetic and the angiogram performed as per standard practice. IVUS-OCT imaging of the culprit vessel using the Novasight Hybrid system is then performed. If image quality of the IVUS-OCT is suboptimal it will be repeated. If the IVUS-OCT catheter cannot cross the lesion, pre-dilatation is performed. The acquired IVUS-OCT images can be used to optimise PCI. Following PCI, angiography is repeated and if the findings are optimal, IVUS-OCT imaging is repeated. If the PCI results are suboptimal further stent optimisation is performed and IVUS-OCT imaging repeated; The procedure is then completed as clinically indicated. The participant will then receive conventional post PCI care
Study: NCT05279807

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofenopril
Description: Film-Coated tablets administered orally once daily according instructions provided by Principal Investigator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofenopril
Description: Film-Coated tablets administered orally once daily according instructions provided by Principal Investigator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Tablets of 5mg and 10mg administered orally once daily according instructions provided by Principal Investigator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Tablets of 5mg and 10mg administered orally once daily according instructions provided by Principal Investigator.
Study: NCT04695210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual peer-to-peer support
Description: See arm description
Study: NCT05898022

Intervention type: DRUG
Group type: OTHER
Intervention: Furosemide (plus potassium chloride)
Description: Furosemide is a loop diuretic that inhibits the reabsorption of sodium and chloride in the proximal and distal tubules as well as the loop of Henle. Participants will receive 2 mg/kg enteral furosemide daily during treatment periods when they receive study drug. To prevent hypokalemia and hypochloremia associated with furosemide use, participants will also receive 1 mg/kg of potassium chloride enterally twice per day when receiving furosemide. Each patient will have 14 days of total exposure to furosemide over the 28-day N-of-1 trial.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo (plus placebo electrolyte solution)
Description: During treatment periods when participants receive placebo, they will receive a volume of sterile water equivalent to the study drug dose. Participants will also receive a placebo electrolyte solution equivalent to the volume of potassium chloride that would be given.
Study: NCT05010915

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation
Study: NCT05053737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: One cycle of Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg. Atezolizumab should be administered within 7 days after initiation of of the first dose of SBRT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: One cycle of Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg. Atezolizumab should be administered within 7 days after initiation of of the first dose of SBRT.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: SBRT will be given 3 times on non-consecutive days over the course of 5 to 7 days. Radiation will target sites of gross disease only to minimized exposure to normal tissue.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: SBRT will be given 3 times on non-consecutive days over the course of 5 to 7 days. Radiation will target sites of gross disease only to minimized exposure to normal tissue.
Study: NCT04534296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early mobilization
Description: Early mobilization is a kind of rehabilitation strategy. When the safe standards are met, early mobilization will be performed on subjects randomized in EM group for 30 minutes each time, twice a day, from Monday to Friday. The detailed mobilization activities include bed repositioning，passive or active range of motion and stretching exercises, passive or active respiratory muscle strengthening, sitting in bed, transfer from lying to sitting at edge of bed. Progressive mobilization goals will be individualized for each subject daily, corresponding to their clinical conditions, developmental maturity, strength and endurance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine care
Description: In this arm, no additional early rehabilitation interventions will be performed except for the routine clinical care, including the ventilation management, spontaneous breathing trials, choice of sedation and analgesia and routine nursing care including repositioning every 2 hours and bed head elevation.
Study: NCT06422949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hilotherm® Cooling treatment
Description: Patient will receive cooling treatment with Hilotherm® at hands and feet level from half an hour before taxol treatment start until half an hour after treatment end
Study: NCT05797506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulforaphane (Avmacol Extra Strength)
Description: 4 Tablets of Sulforaphane (Avmacol Extra Strength) per day in patients with Chronic Kidney Disease, stages 3-4.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: These tablets will be matched placebos and will be provided by Avmacol.
Study: NCT04845737

Intervention type: OTHER
Group type: OTHER
Intervention: sympathetic skin response measurement
Description: Sympathetic skin response(SSR) was studied with upper and lower extremity hand and foot recording of all participants, and amplitude and latency values will be recorded. SSR measurement will be made at room temperature of 25 ºC, while the patients are resting in the supine position. 6 mm silver disc electrodes will be used as the recording electrode.~The relationship between the patients' vitamin D levels and inflammatory response markers and their sympathetic skin responses will be investigated by statistical analysis.

Intervention type: OTHER
Group type: OTHER
Intervention: sympathetic skin response measurement
Description: Sympathetic skin response(SSR) was studied with upper and lower extremity hand and foot recording of all participants, and amplitude and latency values will be recorded. SSR measurement will be made at room temperature of 25 ºC, while the patients are resting in the supine position. 6 mm silver disc electrodes will be used as the recording electrode.~The relationship between the patients' vitamin D levels and inflammatory response markers and their sympathetic skin responses will be investigated by statistical analysis.
Study: NCT05813392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Cognitive Behavioral Therapy for Insomnia
Description: a full self-help digital cognitive behavioral therapy for Insomnia (dCBT-I) through a smartphone APP
Study: NCT05264623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENEO 317 Model 2 excimer laser
Description: TENEO 317 Model 2 excimer laser use for refractive surgery
Study: NCT04955210

Intervention type: OTHER
Intervention: Not applicable（Cohort study）
Description: This is a prospective observational study and does not include interventions.
Study: NCT06636682

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FK-PC101
Description: Up to 7 doses of FK-PC101 will be administered intradermally between Day 1 and Day 180. The immune adjuvant Bacillus Calmette Guérin (BCG) will be given concurrently with Dose 1 (day 1) and Dose 2 (day 8).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: Subject receives Investigator-defined standard of care, excluding adjuvant therapy. If prostate cancer recurs before 12 months after radical prostatectomy, subjects are eligible to receive up to 7 doses of intradermal FK-PC101 vaccine (first 2 given concurrently with BCG).
Study: NCT00013117

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone specialist consultation